Introduction
Approximately 62,000 people with stroke and transient ischemic attack (TIA) are treated in Canadian hospitals each year, of which 53,000 are admitted to acute care. 1 In Canadian hospitals, one patient is treated every 9 min for a stroke or a TIA. 1 Stroke is a leading cause of adult disability; over 400,000 people in Canada are living with its effects. 2 That number is expected to double in the next 20 years. 2 Stroke is the third leading cause of death 3 and costs the Canadian economy more than $3.6 billion a year in physician services, hospital costs, lost wages, and decreased productivity. 4 Hypertension, physical inactivity, unhealthy diets, and our aging population of baby boomers are all significant factors affecting stroke rates in Canada. 3 The 2018 update of the Canadian Stroke Best Practice Recommendations for Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care Practice Guidelines includes a comprehensive summary of current evidence-based recommendations appropriate for use by healthcare professionals across all disciplines that provide care to patients following an acute stroke or TIA within the population of Canada. These guidelines address the first hours and days after stroke occurs, starting with the onset of stroke signs and symptoms through to discharge from the Emergency Department (ED) or acute inpatient care.
The recently published trials showing that endovascular thrombectomy (EVT) is an effective treatment for acute ischemic stroke, including for some patients arriving 16-24 h after last known to be well, have prompted a broader review of emergency systems of care for acute stroke. Increasing timely access to EVT will require an expanded role for paramedics, to ensure that patients with large vessel occlusion are triaged to thrombectomy-capable hospitals, and an expanded role for advanced imaging for patient selection for later arriving patients. This 2018 guideline update provides additional recommendations in these areas.
module. The second notable change in this combined module, Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care is that all recommendations pertaining to hemorrhagic stroke (intracerebral hemorrhage and subarachnoid hemorrhage [SAH] ) after the point of diagnosis have been removed. A new module within the Canadian Stroke Best Practices series focusing on hemorrhagic stroke is in development for release later in 2018. The 6th edition also includes revisions to the recommendations that reflect new evidence available since the previous release of these recommendations 5, 6 for the triage and assessment of risk of recurrent stroke after TIA or nondisabling stroke and suggested urgency levels for investigations and initiation of management strategies (Section 2); updates to management of blood pressure in the first hours following stroke (Section 4); updates, clarification, and consolidation into a single section of initial imaging recommendations in the ED (Section 4); new clinical considerations for treatment of people with stroke of unknown onset time (Section 5.1); updates to EVT recommendations and time windows based on recent evidence from the DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo (DAWN) 7 and the Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke (DEFUSE-3) 8 trial (Section 5.5); revisions to the aspirin recommendations based on additional evidence from the Platelet-Oriented Inhibition in New TIA & Minor Ischemic Stroke (POINT) Trial 9 (Section 6); revisions to recommendations for care of patients experiencing stroke while already in hospital for other causes (Section 8); updates to early mobilization recommendations (Section 9) based on additional analysis from the A Very Early Rehabilitation Trial (AVERT); 10 and revisions to advanced care planning, palliative and end-of-life care recommendations (Sections 10 and 11, respectively).
Guideline development methodology
The Canadian Stroke Best Practice Recommendations development and update process follows a rigorous framework adapted from the Practice Guideline Evaluation and Adaptation Cycle. 11, 12 The methodology has been used in previously published updates 13, 14 and can be found on our Canadian Stroke Best Practices website at www.strokebestpractices.ca. 15 An interdisciplinary group of experts was convened to participate in reviewing, drafting, and revising all recommendation statements. Members with extensive experience in the topic area were selected, as were those who are considered leaders and experts in their field, having been involved in research on the topics addressed in this module. Persons with experience in the review and appraisal of research evidence and individuals (or family members of individuals) who had experienced a stroke were also included either as group members or external reviewers in the development process. The interdisciplinary writing group and external reviewers include stroke neurologists, ED physicians, interventional radiologists, neurosurgeons, nurses, paramedics, family physicians, hospitalists, rehabilitation therapists, epidemiologists, care coordinators, and health system planners. These experts work in a wide range of healthcare settings. This interdisciplinary approach ensured that the perspectives and nuances of all relevant health disciplines and care settings were considered in the development of the recommendations and mitigated the risk of potential or real conflicts of interest from individual members. These guidelines were developed in collaboration with the Canadian Stroke Consortium and the Canadian Association of Emergency Physicians as well as consultation with the Paramedic Chiefs of Canada and the Paramedic Association of Canada. This interprofessional collaboration among these groups was aimed at encouragement of wide-spread adoption of these recommendations and to further drive systems change for more consistent and efficient care of acute stroke patients from the onset of stroke.
A comprehensive systematic literature search was conducted to identify research evidence on the identification and management of persons following acute stroke or TIA. The literature for this module was updated to May 2018. The writing group was provided with comprehensive evidence tables that included summaries of all high-quality evidence identified through the literature searches (evidence tables are available at www.strokebestpractices.ca). Systematic reviews, meta-analyses, randomized controlled trials, and observational studies were included, where available. The writing group discussed and debated the value of the evidence and, through consensus, developed a set of proposed recommendations. Through their discussions, additional research may have been identified and included in the evidence tables if consensus on the value of the research was achieved.
All recommendations are assigned a level of evidence ranging from A (systematic reviews, meta-analyses, multiple homogenous randomized controlled trials), B (single randomized controlled trials, quasi-experimental design with large samples and power), to C (weak evidence, expert opinion achieved by consensus). When developing and including ''C-Level'' recommendations, consensus was obtained within the writing group and validated through the internal and external review process. This level of evidence is used cautiously, and only
International Journal of Stroke, 13 (9) when there is a lack of stronger evidence for topics considered important system drivers for stroke care. In some sections, additional information was identified as important to include, even though it did not meet the evidence criteria for a ''recommendation.'' This information has been included as ''clinical considerations'' intended to provide additional guidance or clarity in the absence of evidence.
After completion of the draft update to the recommendations, the module underwent an internal review by the Canadian Stroke Best Practices Advisory Committee and an external review by Canadian and international experts who were not involved in any aspects of the guideline development. These recommendations were also reviewed by members of the Canadian Stroke Consortium, the Canadian Association of Emergency Physicians, the Paramedic Chiefs of Canada, and the Paramedic Association of Canada. All feedback was reviewed and addressed by the writing group members and the advisory committee to ensure a balanced approach to addressing suggested edits.
All recommendations are accompanied by additional supporting information, including a rationale for inclusion of the topics, system implications to ensure the structural elements and resources are available to achieve recommended levels of care, performance measures to monitor care delivery and patient outcomes as well as implementation resources and a summary of the evidence on which the recommendations were based. Brief summaries of current research evidence are provided at the beginning of each section below. More detailed evidence summaries and links to all evidence tables, and additional knowledge translation information for the recommendations included in this publication can be found at www.strokebestpractices.ca/acutestrokemanagement.
Part 1: Canadian Stroke Best Practice Recommendations for Prehospital and Emergency Department Stroke Care, 6th edition, update 2018
The first minutes and hours from the onset of stroke signs and symptoms are critical and strongly linked to patient outcomes. Rapid assessment, diagnosis, and decision-making could have a significant impact on mortality and long-term recovery and quality of life. Recommendations pertaining to prehospital and ED stroke care involve topics related to all direct care, including investigations, interventions, service delivery, and interactions from first contact with the healthcare system after the onset of stroke symptoms through to discharge from an ED to another healthcare facility (usually with a higher or lower level of stroke care available), to an acute inpatient care unit, or to return to the community. They include topics related to stroke recognition and response, assessment, triage and management of TIA, and mild nondisabling stroke; initial triage and management by emergency medical services (EMS), ED rapid assessment and diagnosis, acute stroke treatments including intravenous thrombolysis with alteplase and EVT, acute antiplatelet therapy, and the early management of patients considered for hemicraniectomy.
Section 1: Stroke awareness, recognition, and response
Many people do not recognize the signs and symptoms of a stroke, or they will attribute them to a less serious health issue and may fail to seek immediate medical attention. In Canada, 40% of people who responded in a recent public poll conducted by the Heart and Stroke Foundation did not know any of the FAST (Face, Arms, Speech, and Time) signs of stroke. 16 Failure of recognition on the part of either those witnessing a stroke or the person experiencing a stroke can initiate a series of delays, beginning with the lag in contacting EMS, and may ultimately decrease a patient's opportunity to receive time-sensitive treatments. The most commonly identified symptoms of stroke among members of the general public are unilateral weakness and slurred speech. [17] [18] [19] The number of public health campaigns designed to increase the recognition of the signs and symptoms of stroke has increased over the past decade. One of the best recognized programs in the healthcare community is FAST. Exposure to these campaigns has proven to be effective, resulting in increased awareness of the signs and symptoms of stroke 20 and an increase in the number of persons who indicated they would call 9-1-1 in response to witnessing specific stroke symptoms. 21 Mass media campaigns have also been shown to be associated with increases in the use of thrombolytic agents following acute stroke. Advani et al. 22 reported that the average number of patients treated with tissue plasminogen activator (t-PA) in a month increased by 54.7%, and the average number of patients treated in the ED increased significantly from 37.3% to 72.8% (an increase of 95.7%, p < 0.001) in the 6-month period following the introduction of a mass media intervention that featured the FAST mnemonic, compared to the preceding 12-month period. In the same study, which also included a telephone survey of 1400 members of the public, the number of people who could name any stroke symptom increased from 66% to 75%.
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Ideally, people experiencing any of the signs of an acute stroke should immediately call 9-1-1 or local emergency services number and go to an ED. Unfortunately, this is not always the case; the reality is that some people experiencing signs of acute stroke may present to an outpatient setting such as a primary care physician or family health team office, community clinic, or urgent care center. People experiencing signs of stroke require rapid assessment, diagnosis, and determination of risk for a recurrent stroke. Patients determined to have TIA, or subacute, nondisabling ischemic strokes who are not candidates for hyperacute treatment with intravenous alteplase or EVT still require timely assessment and management, which can be provided in an outpatient setting. The goal of outpatient management of TIA and nondisabling ischemic stroke is to rapidly identify vascular risk factors, which may have precipitated the initial event, and to initiate treatments to reduce the risk of recurrent events.
Historically, the 90-day risk of recurrent stroke has been estimated to be relatively high, between 12% and 20%, 23, 24 with the greatest risk of recurrence within the first two days following initial symptom onset. The risk of recurrent stroke at two and seven days following a TIA was estimated to be 3.1% and 5.2%, respectively, with lower estimates associated with specialized care. 25 Among patients with multiple risk factors, the seven-day risk of stroke following a TIA can be as high as 36%. 26 With the recent adoption or expansion of the availability of rapid TIA clinics, and urgent evaluation by stroke specialists, the risk of recurrent stroke has been reduced significantly. The increased use and availability of sensitive neuroimaging to identify minor events as well as increased use of antiplatelets, anticoagulants, antihypertensive agents, lipid-lowering agents, and carotid endarterectomy has been shown to significantly reduce the Section 1: Recommendations for stroke awareness, recognition, and response i. All members of the public and all healthcare providers should be educated that stroke is a medical emergency [Evidence
ii. Public and healthcare provider education should focus on recognizing the signs and symptoms of stroke and actions to take when experiencing or witnessing the signs of stroke [Evidence Level C].
iii. Public International Journal of Stroke, 13 (9) risk of major stroke after an initial minor event. A recent study by the TIARegistry.Org group reported updated recurrence rates that were less than half that expected from historical cohorts. This decline was attributed to better and faster access to stroke prevention strategies through rapid-access TIA clinics. Stroke recurrences at days 2, 7, 30, 90, and 365 were 1.5%, 2.1%, 2.8%, 3.7%, and 5.1%, respectively. 27 Similar risk reductions were demonstrated in the Early Use of Existing Preventive Strategies for Stroke (EXPRESS) study. 28 The 90-day risk of recurrent stroke among patients who were referred to a dedicated TIA clinic was 2.1% compared with 10.3% for patients with non-immediate access. 30 Stroke vision, aphasia, neglect (VAN), 31 and the Los Angeles Motor Scale (LAMS), 32 among others. Patients arriving to hospital using EMS following a stroke experience fewer delays in receiving appropriate diagnostic tests (e.g., brain imaging) and are more likely to receive intravenous thrombolysis and mechanical thrombectomy, if eligible. Transport by EMS is also safer and enables patients to be triaged to appropriate hospitals that provide specialized stroke services. Approximately 63% of all patients who seek acute care for stroke in Canada arrive at the ED by ambulance 1, 33 ; Patients are also more likely to receive timely transportation and care when prenotification systems, including the use of trained EMS dispatchers, are adopted. Hospital prenotification typically involves informing ED physicians and other relevant personnel (blood and EKG technicians, radiologists, and pharmacologists) of the arrival of a potential stroke patient. The results from several studies indicate that a significantly higher proportion of patients are treated with thrombolytic agents after EMS dispatchers completed training aimed at improving their ability to detect suspected stroke patients. 34, 35 Watkins et al. 36 reported that the percentage of stroke patients correctly dispatched as suspected stroke increased significantly (63% to 80%, p < 0.01) after EMS dispatchers completed training. Process times associated with thrombolysis treatment may also be shortened for patients arriving to hospitals by EMS with prenotification protocols. In a study that included 27,566 patients who were identified as suspected stroke patients by dispatchers, the mean times associated with transportation, including time to scene, time at scene, time from scene to destination, and total transportation time were all significantly reduced, compared to persons whose final diagnosis was stroke, but who were not identified by dispatchers. 35 Berglund et al. 34 reported that patients in the Hyper Acute STroke Alarm (HASTA) Study assigned an upgraded priority level by dispatching personnel experienced fewer delays along the chain of stroke care from symptom onset to arrival at a stroke unit and were more likely to be treated with t-PA compared with patients who had been assigned to a standard-priority level by the emergency medical communications center. Patients classified as Priority Level 1 received thrombolysis more often than those classified as priority Level 2 (24% vs. 10%, p < 0.001) and a greater number arrived at the stroke unit within 3 h of symptom onset (61% vs. 46%, p ¼ 0.008). ii. EMS communications center: All regions should implement a dispatch process through the EMS communications center to recognize the probable stroke signs (such as FAST-Face, Arms, Speech, and Time), potential stroke diagnosis, and need for priority response to the scene and transport to a hospital capable of providing acute services for the rapid diagnosis and time-sensitive treatment of stroke (such as neuroimaging and acute thrombolysis) [Evidence Level C].
iii. After dispatching the ambulance, it is recommended that emergency medical system communications center personnel provide pre-arrival instructions to the person reporting the stroke (such as unlock door, move pets, determine stroke symptom onset time, determine current medications) in order to expedite and optimize prehospital care [Evidence Level C]. Note: If the person experiencing the signs of stroke is the one to contact EMS, they may not be able to comply with these requests.
Paramedic on-scene management
Note: On-scene goal is to ''recognize and mobilize''-it is of the utmost importance to proceed rapidly and safely to transport suspected stroke patients, as on-scene management for stroke patients is limited. iii. On-scene time with suspected stroke patients should be as short as possible; ideally a median time of 20 minutes or less* for patients who present within the 4. v. Prior to transport, it is recommended that paramedics on-scene provide instructions to the patients' family, including recommending that the family/decision-maker accompany the patient to hospital or be accessible by phone for decisionmaking, as well as confirming time last known well, and providing required information about existing health conditions, current medications, and other information as needed [Evidence Level C].
3.3 Transport of suspected stroke patients i. Direct transport protocols must be in place to facilitate the transfer of suspected acute stroke patients who are potentially eligible for thrombolytic and/or EVT to the most appropriate acute care hospital capable of providing services for the diagnosis and treatment of acute stroke [Evidence Level C].
ii. It is recommended that direct transport protocol criteria be based on:
a. an EMS system set up to categorize patients exhibiting signs and symptoms of an acute stroke as a high priority for International Journal of Stroke, 13 (9) iii. Patients with suspected stroke should be triaged by EMS personnel as Canadian Triage Acuity Scale (CTAS) Level a. Information required includes time of stroke onset or time of symptom recognition or time when last known well (as accurate as possible), total symptom duration at anticipated arrival in the ED, presenting signs and symptoms of stroke, Glasgow Coma Scale (GCS) score, CTAS triage score (or P-CTAS), patient age, current use of antithrombotic drugs, and expected time of arrival at the receiving hospital. Refer to Box 3 for details of information required during prenotification.
v. Patients who are considered ineligible for thrombolytic therapy or EVT should still be transported urgently (either directly or indirectly) to the closest hospital capable of providing services for the diagnosis and treatment of stroke (ED, access to neurovascular imaging, stroke unit, and stroke expertise on site or through Telestroke modalities) [Evidence Level C]. 1. Direct transport in many regions involves two considerations: (1) patients who may be eligible for intravenous alteplase may be directed to the closest center (primary/advanced stroke center or comprehensive stroke center) and, (2) patients who are determined to be a likely candidate for EVT may proceed directly to an EVT-enabled comprehensive stroke center OR to the primary center first to rapidly receive intravenous alteplase, and then be considered for transport to the EVT-enabled comprehensive stroke center.
Hospital arrival and EMS handover to Emergency
2. Screening for potential stroke and likelihood of large vessel occlusion should be done early in the on-scene assessment. If the stroke screen is positive, all actions on-scene from that point should be directed at moving to the ambulance and beginning transport. All treatments not immediately required (IVs, etc.) could be undertaken while the patient is en route to the hospital or after hospital arrival. Scene time (location of patient at time of stroke) is an important variable that EMS professionals can control and needs to be monitored very closely. Time lost due to inefficient scene care cannot be made up during subsequent transport to hospital, regardless of the use of lights and sirens.
3. Prenotification contact with the receiving ED should be as soon as possible; where possible, the paramedics and receiving ED physician or stroke team member should speak en route.
4. The term ''eligible'' for acute stroke therapies is usually defined within regional jurisdictions. Generally, it refers acute stroke patients within the 4.5-h time window for medical thrombolytic therapy; however, local definitions should be clarified during implementation of these recommendations.
5. For EVT, the strongest evidence for benefit exists for treatment received within 6 h of stroke symptom onset (with or without concurrent medical thrombolytic therapy). However, randomized trial evidence exists to show that highly selected patients may be considered for EVT based upon neurovascular imaging within a 24-h window from symptom onset.
6. In some stroke centers, the alteplase treatment time window may extend beyond 4.5 h under the directive of a research or local protocols. These factors should be taken into consideration during transport and agreements should be in place between the provincial/regional EMS system and the receiving hospitals.
7. In regions with a specialized pediatric hospital, every attempt should be made to transport children with signs of stroke to that specialized pediatric hospital.
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Patients require immediate evaluation when presenting to the ED with suspected stroke or TIA. Systems of care must be in place to ensure highly coordinated rapid assessment and access to imaging. In this update, recommendations for urgent imaging have been clarified, expanded, and consolidated all in this section. For those patients presenting with TIA, their risk for imminent stroke (i.e., within one week) can be evaluated, and investigations/treatment initiated to prevent a future stroke (refer to Section 2 for more information). Standard assessments for patients with suspected acute stroke include a neurological examination, immediate neurovascular imaging, monitoring of vital signs, blood work, cardiovascular investigations, and dysphagia screens. Immediate access to brain and vascular imaging is required for all patients arriving to hospital with suspected stroke or TIA. A non-contrast CT (NCCT) scan or MRI should be used as first line initially to identify the presence of stroke and stroke type-ischemic or of hemorrhagic origins. Although MRI has been shown to be more sensitive in detection of the early changes associated with ischemia, especially in patients with small infarcts, 37 timely access to the technology is not widely available in Canada, in particular in the context of an acute stroke. In MRI-equipped centers, patients with suspected stroke may not get immediate access to this technology, which could lead to delays in treatment decisions. Combined multimodal vascular imaging with angiography, and in highly selected cases perfusion scans, with CT or MRI has the potential to identify patients with an ischemic penumbra and potentially viable brain tissue who may be appropriate for acute reperfusion therapies. Perfusion scans can be especially useful in selecting patients eligible for endovascular therapy in the 6-24 h window whereas in the 0-6 h timeframe, most cases can be selected with the use of CT and CTA alone. For all potential stroke patients, once adequate breathing and circulation have been secured, neuro-imaging must be the highest priority on arrival to hospital. Blood work and other assessments such as an electrocardiograph can be done after imaging in most cases.
The initial management of elevated blood pressure in acute stroke patients remains controversial, given the lack of evidence to clearly guide practice. In ischemic stroke, high initial blood pressure has been associated with cerebral edema or hemorrhagic transformation, but rapid reduction of blood pressure, regardless of the degree of hypertension, may also be harmful. Aggressive efforts to lower blood pressure may decrease perfusion pressure, which may worsen ischemia. 38 Since optimal blood pressure targets are not yet known, the current, consensus-based recommendation for patients who are not candidates for thrombolytic therapy is to lower blood pressure only when systolic pressure exceeds 220 mm Hg or when diastolic pressure exceeds 120 mm Hg. For patients who are candidates for thrombolytic therapy, since elevated blood pressure (systolic blood pressure (SBP) !185 mm Hg or diastolic blood pressure (DBP) ! 110 mm Hg) is a contraindication to the use of thrombolytics, blood pressure must be reduced to avoid hemorrhagic complications. Results from the blood pressure-lowering arm of the ENCHANTED trial, when released, will provide additional information to guide patient management. 39 Box 3A: Core information required by dispatch, paramedics, and receiving healthcare facility . Where permitted, name, date of birth, and health card number of patient. Note: In general, this confidential personal health information is not allowed to be transmitted by radio; however, some provinces have been able to receive a waiver and the restriction lifted for emergency cases such as stroke. There is no evidence to support the prophylactic use of anticonvulsant medications in patients with acute stroke and there is some evidence to suggest possible harm with negative effects on neural recovery. ii. All patients with suspected acute ischemic stroke who arrive within 4.5 h and are potentially eligible for intravenous thrombolysis (refer to criteria in Box 4A) should undergo immediate brain imaging with non-contrast CT (NCCT) without delay to determine eligibility for thrombolysis [Evidence Level A].
iii. All patients with suspected acute ischemic stroke who arrive within 6 h and are potentially eligible for EVT (refer to criteria in Box 4B and Section 5) should undergo immediate brain imaging non-contrast CT and CT angiography (CTA) without delay, from arch-to-vertex including the extra-and intra-cranial circulation, to identify large vessel occlusions eligible for endovascular thrombectomy [Evidence Level A].
Note: Primary stroke centers that cannot do CTA should have pre-planned arrangements for rapid transfer of appropriate patients. They should complete NCCT and offer intravenous alteplase as appropriate and then rapidly transfer the patient to a CSC for more advanced imaging and consideration for EVT. International Journal of Stroke, 13 (9) iii. Although no optimal glucose target has been identified, it is reasonable to treat hyperglycemia which has been associated with hemorrhagic transformation when treating with IV alteplase thrombolysis [Evidence Level C].
Additional Management Considerations in the Emergency Department i. Chest x-ray:
A chest x-ray should be completed when the patient has evidence of acute heart disease or pulmonary disease [Evidence Level B] . Unless a patient is hemodynamically unstable, chest x-ray can be deferred until after a decision regarding acute treatment and it should not delay assessment for thrombolysis and EVT.
ii. 1. There is no evidence to support the practice of routine reversal of anticoagulation, either during non-thrombolytic conservative care or in order to give alteplase in patients presenting with acute ischemic stroke who are on warfarin or direct oral anticoagulants (DOACs). EVT may be considered despite anticoagulation if patients are otherwise eligible. International Journal of Stroke, 13 (9) Section 5: Acute ischemic stroke treatment
The weight of evidence from many large, international randomized controlled trials over the previous 20þ years clearly indicate that treatment with intravenous alteplase, administered within 3-4.5 h of symptom onset improves stroke outcome, reducing the risks of death and or disability substantially. 40 The focus of more recent lines of enquiry have been directed at the potential non-inferiority of lower doses of alteplase (e.g., 0.6 vs. 0.9 mg/kg), 41 different thrombolytic agents (e.g., tenecteplase), 42 issues related to the treatment window, 43, 44 the use of anticoagulant reversal agents, 45, 45 and the use of specialized imaging to identify additional, potentially eligible candidates for thrombolysis beyond the 4.5-h time window. The results from the Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (WAKE-UP) trial 46 demonstrated that highly selected patients with mild-to-moderate ischemic strokes and an unknown time of symptom onset, treated with alteplase, may also benefit from treatment. Patients in this trial who had unknown time of stroke onset, were Box 4C: Advanced CT imaging criteria for EVT Selection 1. Sites using CTP imaging should utilize software that provides reproducible objective measurements of ischemic core and penumbra.
2. An occluded proximal intracranial artery (carotid artery, M1 segment of the MCA, or proximal M2 divisions) of the anterior circulation, which is a target lesion amenable to EVT. The location of occlusion is defined by an arterial phase CTA from ascending aorta to the vertex of the head. Inclusion of the aortic structures allows planning and assessment of the technical feasibility of an endovascular approach to the occluded intracranial artery.
3. There is evidence to suggest that moderate-to-good pial collateral filling (as defined by CTA) or evidence of CTP mismatch predict a better response to EVT. 4 . Stroke imaging on-site with 24-h access, seven days a week, including a CT scanner (i.e., third-generation or higher helical scanner) with programming for CTA; multiphase or dynamic CTA or CTP imaging can also be used if available on-site.
Note: ASPECTS score is one tool to estimate core: A small-to-moderate ischemic core can be defined by an ASPECTS score of 6 or higher on NCCT or areas of low cerebral blood volume (CBV) or cerebral blood flow (CBF) maps on CTP imaging.
Box 4D: Endovascular selection imaging criteria for patients arriving later than 6 h of stroke onset 1. Sites using CTP imaging should utilize software that provides reproducible objective measurements of ischemic core and penumbra. 2. An occluded proximal intracranial artery (carotid artery, M1 segment of the MCA, or proximal M2 divisions) of the anterior circulation, which is a target lesion amenable to EVT. The location of occlusion is defined by an arterial phase CTA from ascending aorta to the vertex of the head. Inclusion of the aortic structures allows planning and assessment of the technical feasibility of an endovascular approach to the occluded intracranial artery. 3. Imaging and clinical evidence of small core and large area at risk, defined in the trials as either: a. NIHSS ! 10 and either 0-21 ml core infarct (!80 years old) or 0-31 ml core infarct (<80 years old), or NIHSS ! 20 and 31 to <51 ml core infarct and <80 years old (DAWN trial criteria). 7 
OR
b. Ischemic core volume is <70 ml, mismatch ratio is !1.8 and mismatch volume* is !15 ml (DEFUSE3 trial criteria). 8 Box 4B: Endovascular selection imaging criteria for patients arriving within 6 h of stroke onset 1. A small-to-moderate ischemic core (which may be estimated as an ASPECT score of 6 or higher).
For patients with a large ischemic core, such as with an ASPECT score less than 6, the decision to treat should be based on the potential benefits and risks of the treatment, made by a physician with stroke expertise in consultation with the neuro-interventionalist, and patient and/or family/substitute decision-makers. 2. Intracranial artery occlusion in the anterior circulation, including proximal large vessel occlusions in the distal internal carotid artery or middle cerebral artery (MCA) and immediate branches. 3. For patients with basilar artery occlusions, the decision to treat with EVT should be based on the potential benefits and risks of the therapy, made by a physician with stroke expertise in consultation with the neuro-interventionist, and the patient and/or decision-makers. Note: There are ongoing randomized trials in this area and this issue will be reviewed once the results become available.
Refer to Section 5 for additional EVT clinical inclusion and exclusion criteria.
International Journal of Stroke, 13 (9) outside the 4. The lack of confidence on safety endpoints was in part related to early termination of the trial, with 503 of the intended 800 randomized, due to slow enrollment and lack of funds. Recent attention has been focused on mechanical revascularization with specialized devices. To date, many major RCTs have been completed for which results have been published, whereby endovascular therapies were compared with best medical management. [47] [48] [49] [50] [51] Several trials are still ongoing or have yet to report their findings. The results from most of these trials indicate that rapid endovascular treatment using second-generation devices is a safe and effective treatment for patients with anterior circulation ischemic strokes with a proximal occlusion, when performed within 6 h of symptom onset, with more limited data in the 6-to -12-h treatment window. The estimated number of patients needed-to-treat with mechanical thrombectomy to achieve a modified Rankin Scale score of 0-2, 90 days post procedure, ranged from 4 49 to 8 47 among these trials. The recent results from both the DEFUSE-3 and DAWN trials 7, 8 suggest that the treatment window for mechanical thrombectomy may be wider than previously understood for highly selected patients. Patients in the DAWN trial 7 were eligible for treatment up to 24 h after last known well, while patients in the DEFUSE-3 8 trial were eligible for up to 16 h. In both trials, a significantly higher proportion of patients had achieved recanalization at 24 h and were independent at 90 days compared with treatment with best medical management (49% vs. 13% 7 and 44.6% vs. 16.7% 8 ). In both trials, there was no significant difference between groups in the proportion of patients with symptomatic intracerebral hemorrhage at 24 h.
Recent evidence from the EXTEND-IA TNK trial, 52 which included a small number of patients with ischemic stroke with arterial occlusion, suggested that intravenous tenecteplase (TNK) was superior to alteplase with respect to arterial recanalization when given prior to mechanical thrombectomy. While a significantly higher percentage of patients in the tenecteplase group achieved the primary outcome (substantial reperfusion, defined as !50% of the involved territory or the absence of retrievable thrombus at initial angiographic assessment: 22% vs. 10%), the percentage of patients who were functionally independent or who had achieved an excellent outcome at 90 days did not differ between groups; neither did the percentage of patients who experienced early neurological improvement. It was not powered to demonstrate an effect on clinical outcomes. Further evidence from ongoing trials (TASTE (ACTRN12613000243718), TEMPO-2 (NCT02398656), TWIST (NCT03181360), and ATTEST-2 (NCT02814409)) is required before changes to clinical practice can be recommended.
Section 5: Recommendations for the acute ischemic stroke treatment
Box 5A: Criteria for stroke centers providing acute ischemic stroke treatment Within the Canadian Stroke Best Practices Optimal Stroke Services Framework, all hospitals in Canada have been identified as comprehensive, advanced/primary, general non-stroke acute care hospitals, or basic healthcare facilities (generally small rural and remote sites). Comprehensive and advanced/primary stroke centers are those that have coordinated stroke care services, including CT imaging and alteplase administration available on-site.
Some comprehensive stroke centers and a select group of advanced/primary stroke centers will be able to provide EVT (with mechanical embolectomy) for acute ischemic stroke. To provide EVT, centers must meet the following criteria:
. A designated stroke team which includes physicians with stroke expertise (stroke neurologist or other physicians with advanced stroke training); stroke nurses and advanced practice nurses (and/or nurse practitioners); neurosurgeons; (neuro)-radiologists, Emergency Physicians; critical care physicians; rehabilitation therapists (physical therapists, occupational therapists, speech-language pathologists, and dieticians), pharmacists, and social workers.
. Neurointerventional expertise on-site with available 24-h access, seven days a week. . On-site neurosurgery support and neurocritical care services. . Stroke imaging on-site with 24-h access, seven days a week, including a CT scanner (i.e., third-generation or higher helical scanner) with programming for CTA. Multiphase or dynamic CTA or CTP imaging can also be used if available on-site. MR imaging (MRI, MRA, and MRP) may be considered if available on site and will not delay acute stroke treatments.
. Capability to administer intravenous alteplase. . Designated stroke unit on-site-a geographically defined hospital unit dedicated to the care of stroke patients, with protocols in place that follow current evidence-based stroke best practice recommendations for acute stroke management and early access to rehabilitation assessment and therapy.
Patient selection for acute ischemic stroke treatments
Note: Treatment benefits from revascularization decreases over time as an estimated 1.9 million brain cells die every minute following stroke onset (Saver J. Stroke 2006;37:263-266); therefore, all patients with stroke should be treated as fast as possible to maximize potential for the best outcomes, and the new extended time windows should not be interpreted to mean that time to treatment can be slowed down in any way.
i. All patients with disabling acute ischemic stroke within 24 h of stroke symptom onset or last known well should be rapidly screened clinically and with neurovascular imaging [Evidence Level B].
ii. All patients with disabling acute ischemic stroke who can be treated within the indicated time windows must be screened without delay by a physician with stroke expertise (either on-site or by telemedicine/telestroke consultation) to determine their eligibility for both intravenous alteplase (within 4.5 h from stroke symptom onset) and/or interventional treatment with EVT (within a 6-h window from stroke symptom onset). iv. There are randomized controlled trials which indicate that highly selected patients with disabling stroke symptoms may benefit from EVT up to 24 h from the time they were last known well, including patients with stroke on awakening, and patients should be considered for eligibility within the extended time window on a case-by-case basis [Evidence Level A]. Note: These patients were selected using CTP or diffusion-weighted criteria (as defined in Box 5C below). 
Clinical considerations:
1. One recent multicenter randomized double-blind placebo controlled trial compared alteplase to placebo for ischemic stroke patients with unknown time of onset, using MRI selection criteria (DWI-FLAIR mismatch). It included ischemic stroke patients who were not candidates for EVT and who would otherwise have met the criteria for acute intravenous alteplase administration 46 (refer to Box 5B for alteplase criteria) This trial demonstrates a clinical benefit of intravenous alteplase administered more than 4.5 h from the time the patient was last known well in patients where onset time is unknown (no upper time limit defined). If intravenous alteplase is considered after 4.5 h, a consultation with a physician with stroke expertise should be obtained. Selection of patients for intravenous alteplase in patients presenting after 4.5 h on the basis of CT, CTA, and CTP remains unproven at this time. MRI scanning can be challenging to obtain urgently in an ED setting. This must be considered in decision-making and not delay decisions regarding EVT eligibility.
Imaging criteria
Refer to Section 4.2 for detailed recommendations and Boxes 4A, 4B, 4C, and 4D for selection criteria for neuroimaging.
i. Patients should be considered for revascularization treatment when there is no evidence of extensive early infarct changes [Evidence Level B], in consultation with physicians with stroke expertise. Note: One possible tool to assess infarct change is the ASPECT score: www.aspectsinstroke.com a. Timely access to CT or MR perfusion scanning can also be used to demonstrate a perfusion mismatch and to determine the extent of the ischemic core [Evidence Level A], especially in patients beyond 6 h from last known well, including patients with stroke on awakening.
ii. For EVT, patients should have a proximal occlusion in the anterior circulation [Evidence Level A]. Refer to Box 5C for EVT inclusion and exclusion criteria. Caution: The dosing of alteplase for stroke is not the same as the dosing protocol for administration of alteplase for myocardial infarction.
Intravenous thrombolysis with alteplase
iii. Hospital inpatients that present with a sudden onset of new stroke symptoms should be rapidly evaluated by a specialist team and provided with access to appropriate acute stroke treatments (including thrombolysis and EVT) [Evidence Level B]. Note: Once stroke occurs to an existing inpatient, all other sections of the Canadian Stroke Best Practice modules apply to these patients for assessment, diagnosis, management, and recovery. 2. Intravenous alteplase is considered the standard of care and is currently the only approved thrombolytic agent for acute ischemic stroke treatment. There are other drugs being investigated; however, at this time are not approved for use in stroke patients.
3. Alteplase administration for patients on DOACs: alteplase should not routinely be administered to patients on DOACs presenting with acute ischemic stroke. EVT may be considered in in these cases for eligible patients, and decisions should be based on individual patient factors and assessment of benefit and risk.
a. In comprehensive stroke centers with access to specialized tests of DOAC levels and reversal agents, thrombolysis could be considered, and decisions should be based on individual patient characteristics, in consultation with hematology specialists, patients, and their families.
4. There remain situations in which clinical trial data to support the use of intravenous thrombolytic therapy is more limited.
In these situations, urgent consultation with a stroke expert is recommended alongside the clinical judgment of the treating physician and discussion with the patient or substitute decision-maker.
a. This may apply to pediatric stroke (newborn to age 18 years) and pregnant women who experience an acute ischemic stroke. Refer to Canadian Stroke Best Practices Management of Acute Stroke during Pregnancy Consensus Statement for further information
Acute Endovascular Thrombectomy Treatment (EVT)
Refer to Section 4.2 and Boxes 4B, 4C, and 4D for detailed recommendations on neuroimaging-based selection criteria.
i. EVT should be offered within a coordinated system of care including agreements with EMS, access to rapid neurovascular (brain and vascular) imaging, coordination between EMS, the ED, the stroke team and radiology, local expertise in neurointervention, and access to a stroke unit for ongoing management [Evidence Level A].
ii. EVT 2. Device selection should be at the discretion of the interventionalists based on clinical and technical factors during the procedure.
3. For patients undergoing EVT following administration of alteplase, there should not be a delay in proceeding to EVT to determine clinical effectiveness of alteplase.
Box 5B: Criteria for acute thrombolytic therapy with intravenous alteplase
Refer to Section 4.2 and Box 4A for detailed recommendations on neuroimaging-based selection criteria These criteria are designed to guide clinical decision-making; however, the decision to use alteplase in these situations should be based on the clinical judgment of the treating physician. The relative benefits of alteplase therapy versus any potential risks or contraindications should be weighed on an individual basis.
IV alteplase treatment inclusion criteria
Diagnosis of ischemic stroke causing disabling neurologic deficit in a patient who is 18 years of age or older. For adolescents, decision to administer alteplase should be based on clinical judgment, presenting symptoms, and patient age; and, if possible, consultation with a pediatric stroke specialist. Time from last known well (onset of stroke symptoms) less than 4.5 h before alteplase administration. * For patients beyond 4.5 hours refer to Section 5.1 Clinical considerations for more information.
Absolute exclusion criteria
Any source of active hemorrhage or any condition that could increase the risk of major hemorrhage after alteplase administration. Any hemorrhage on brain imaging.
Relative exclusion criteria (requiring clinical judgment based upon the specific situation)
Historical
History of intracranial hemorrhage.
International Journal of Stroke, 13 (9) Box 5C: Inclusion criteria for EVT Refer to Section 4.2 and Boxes 4B, 4C, and 4D for detailed recommendations on neuroimaging-based selection criteria 1. If intravenous alteplase is given in conjunction with EVT, refer to Box 5B for additional inclusion criteria. 2. Age: Patients under 18 years of age. There is no current evidence for use of EVT in pediatric populations and the decision to treat should be based on the potential benefits and risks of the therapy, made by a physician with Pediatric stroke expertise in consultation with the patient and/or family/substitute decision-makers. 3. Premorbid condition criteria: In general, functionally independent and life expectancy greater than three months.
Imaging:
a. A small-to-moderate ischemic core (such as with ASPECTS score of 6 or higher). For patients with large ischemic core, such as with ASPECTS score less than 6, the decision to treat should be based on the potential benefits and risks of the treatment, made by a physician with stroke expertise in consultation with the neuro-interventionalist, and patient and/or family/substitute decision-makers. b. Intracranial artery occlusion in the anterior circulation, including proximal large vessel occlusions in the distal ICA or MCA and immediate branches. c. For patients with basilar artery occlusions, the decision to treat with EVT should be based on the potential benefits and risks of the therapy, made by a physician with stroke expertise in consultation with the neuro-interventionist, and the patient and/or decision-makers. 5. Time to treatment: The decision to proceed with EVT should be shared between the physician with clinical stroke expertise and the neuro-interventionalist, who will make use of the available imaging information as is indicated. Details regarding imaging parameters commonly used in the literature are included in Box 4B -4D. a. Specifically:
i. Patients should have immediate neurovascular imaging (see above) to determine eligibility. Patients can be considered for imaging within a 24-h window from stroke onset or last known well. ii. For patients presenting less than 6 h from onset of stroke symptoms or last known well to initiation of treatment (i.e., arterial puncture), all patients who meet eligibility criteria should be treated. iii. For patients presenting between 6 and 24 h from last seen well, highly selected patients may be treated if they meet clinical and imaging criteria, and based on local protocols and available expertise in EVT. 56 using three RCTs suggested that the greatest reduction in early stroke recurrence was associated with aspirin monotherapy given to patients presenting with mild and moderately disabling stroke. Aspirin therapy was not associated with a significant reduction in stroke recurrence among those with a severe stroke.
Dual therapy using clopidogrel plus aspirin has also been evaluated for the prevention of recurrent stroke following minor events. In CHANCE, 57 significantly fewer patients in the clopidogrel (75 mg/day) þ aspirin (75 mg/day) group experienced a stroke within 90 days, compared with patients in the aspirin only group (8.2% vs. 11.7%, HR ¼ 0.68, 95% CI 0.57-0.81, p < 0.001). Although the CHANCE trial suggested a benefit of short-term dual therapy, since the study was performed exclusively in China, the generalizability of the results in a North American population was questioned. This potential limitation appears unsubstantiated based on the recent results of the POINT trial 9 where the majority of the 4881 patients recruited were from centers in the United States. Eligibility criteria for POINT were similar to that of the CHANCE trial, 57 although the intervention differed somewhat (dual antiplatelet for 90 vs. 21 days, and loading doses of 600 vs 300 mg in the POINT and CHANCE trials, respectively). Patients in POINT 9 were randomized to receive 81 mg aspirin þ 75 mg clopidogrel or aspirin þ placebo for 90 days. The risk of ischemic stroke was significantly lower in the clopidogrel plus aspirin group (4.6% vs. 6.3%; HR ¼ 0.72, 95% CI 0.56-0.92, p ¼ 0.01), although the risk of major hemorrhage was significantly increased (0.9% vs. 0.4%, HR ¼ 2.32, 95% CI 1.10-4.87, p ¼ 0.02). The authors estimated that for every 1000 patients treated with clopidogrel plus aspirin for 90 days, 15 ischemic strokes would be prevented but 5 major hemorrhages would result. For these reasons, we have limited the new recommendation for dual antiplatelet therapy to 21-30 days only. ). In all trials, surgery was associated with a significant reduction in the risk of mortality up to one-year follow-up. The results of these trials when pooled in a Cochrane review 61 indicated that hemicraniectomy was associated with a significantly reduced risk of death at the end of follow-up (OR ¼ 0.19, 95% CI 0.09-0.37) and in the risk of death or severe disability (mRS > 4) at 12 months (OR ¼ 0.26, 95% CI 0.13-0.51). A more recent systematic review, which included the results from seven trials, 62 documented that the odds of a favorable outcome (mRS 0-3) and survival at 6-12 months were significantly increased for patients in the hemicraniectomy group with odds ratios of 2.04 (95% CI 1.03-4.02, p ¼ 0.04) and 5.56 (95% CI 3.40-9.08, p < 0.001), respectively. The benefit of surgery in older patients is less certain. While the surgery may be lifesaving, it can result in survival with moderate or severe disability. In the DESTINY II trial, 63 a significantly higher proportion of patients in the surgical group were alive and living without severe disability at six months (38% vs.18%, OR ¼ 2.91, 95% CI 1.06-7.49, p ¼ 0.04). However, no patients in either the surgical or medical care groups had overall good outcomes (mRS score of 0-2) at 6 or 12 months and most of the survivors required assistance with most bodily needs. Discussions with patients and or substitute decision-makers should include information about likely outcomes, and potential for survival with significant disabilities that may add increased burden to families.
Refer to Canadian Stroke Best Practice Recommendations Secondary Prevention of Stroke Module Sections 6 and 7 for additional information on use of antithrombotic agents beyond the acute period Clinical considerations:
1. Patients with very high-risk TIA or minor ischemic stroke caused by high-grade carotid stenosis who are candidates for urgent carotid endarterectomy or carotid stenting, should be reviewed with the interventionalist or surgeon to determine the appropriate timing and selection of antiplatelet agent(s). In some circumstances it may be appropriate to use aspirin monotherapy rather than dual antiplatelet therapy if carotid endarterectomy is planned urgently, to reduce perioperative bleeding risk.
2. For patients on dual antiplatelet therapy, GI protection may be considered in patients at higher risk of GI bleeding [In POINT (90-day study) extracranial bleeding events were 0.9% in the dual antiplatelet therapy group and 0.4% in the monotherapy group; in CHANCE (21-day study) extracranial bleeding events were 0.3% in the dual antiplatelet therapy group and 0.3% in the monotherapy group.] Box 6A: VERY HIGH risk for recurrent stroke (symptom onset within last 48 h):
Patients who present within 48 h of a suspected TIA or nondisabling ischemic stroke with the following symptoms are considered at highest risk of first or recurrent stroke: transient, fluctuating or persistent unilateral weakness (face, arm and/or leg); transient, fluctuating or persistent language/speech disturbance; and/or fluctuating or persistent symptoms without motor weakness or language/ speech disturbance (e.g., hemibody sensory symptoms, monocular vision loss, hemifield vision loss, þ/À other symptoms suggestive of posterior circulation stroke such as binocular diplopia, dysarthria, dysphagia, ataxia).
For additional risk stratification, refer to Section 2 of this module.
Section 7: Recommendations for the early management of patients considered for hemicraniectomy 7 .0 Hemicraniectomy should be considered in patients in the early stages of extensive (malignant) MCA territory ischemic stroke as a life-saving measure for patients willing to accept a significant risk of living with a degree of disability that may leave them dependent on others for their activities of daily living [Evidence Level A for patients age 18-60 years; Evidence Level B for patients 60-80 years]. This section includes recommendations related to management of acute stroke patients once diagnosis is confirmed and decisions made regarding early acute stroke treatments. It involves all direct care, investigations, interventions, service delivery, and interactions occurring during the time a person who has had a stroke is admitted to inpatient care within an acute care hospital. The principal aims of this phase of care are to identify the nature and mechanism of stroke, prevent stroke complications, promote early recovery, and (in the case of severest strokes) provide palliation or end-oflife care. This acute phase of care is usually considered to have ended either at the time of acute stroke unit discharge or by 30 days of hospital admission. Section 8 also provides guidance for people who experience an acute stroke while already in hospital for another condition. ii. Posterior fossa decompression can be considered in selected patients with significant cerebellar stroke with evidence of mass effect and/or hydrocephalus [Evidence Level C].
iii. If a potential patient's location is initially outside a comprehensive stroke center, the patient should have expedited transfer to a tertiary or quaternary center where advanced stroke care and neurosurgical services are available [Evidence Level C].
Initial clinical evaluation
i. Urgent consultation with a stroke specialist for assessment and for determination to involve neurosurgery [Evidence Level C].
ii. For patients who meet criteria for potential hemicraniectomy during initial assessment, an urgent neurosurgical consultation should be initiated in-person, by telephone, or using telemedicine (Telestroke services) [Evidence Level C].
iii. Initiate a discussion with patient, family members, and legal decision-maker regarding a potential hemicraniectomy [Evidence Level C]. a. Key issues to be discussed with the patient and/or alternate decision-makers include stroke diagnosis and prognosis if untreated, the risks of surgery, the possible and likely outcomes following surgery including the odds of living with severe disability, and the patient's previously expressed wishes concerning treatment in the event of catastrophic illness and probability of living with severe handicap. b. The discussion with the patient and decision-makers should state more clearly that there is a survival benefit, but an uncertain impact on quality of life and disability. Furthermore that even with treatment, a good outcome (MRS 0-2) is rare. International Journal of Stroke, 13 (9) Section 8: Acute stroke unit care
Patients who are admitted to stroke units are more likely to survive, return home, and regain their independence compared to patients who are admitted to non-specialized units. Stroke unit care is characterized by an interdisciplinary stroke team, composed of physicians, nurses, physiotherapists, occupational therapists, speech-language pathologists, and pharmacists, among others with a special interest and expertise in stroke care, who are dedicated to the management of patients recovering from stroke. The other defining feature of a stroke unit is beds that are located within a geographically defined area and are occupied exclusively by patients with stroke. 64 The most recent update of the Stroke Unit Trialists' Collaboration 64 included 28 randomized and quasi-randomized trials comparing stroke unit care with an alternative, less organized form of care (e.g., general medical ward). After a median one-year follow-up, stroke unit care was associated with a significant reduction in death (OR ¼ 0.76, 95% CI 0.66-0.88, p ¼ 0.0001), death or institutionalization (OR ¼ 0.76, 95% CI 0.67-0.86, p ¼ 0.0001), and death or dependency (OR ¼ 0.80, 95% CI 0.67-0.97, p < 0.00001). Moreover, stroke unit care was found to be superior regardless of sex, age, or stroke severity. In Canada, access to stroke unit care varies by region. Within our large comprehensive stroke centers, over 70% of stroke patients are admitted to stroke units. For patients cared for in primary stroke centers, just over half of all acute ischemic stroke patients spend any time on an acute stroke unit. 1 Systems improvement to increase the number of patients cared for on a stroke unit is an imperative. i. Patients should be admitted to a stroke unit which is a specialized, geographically defined hospital unit dedicated to the management of stroke patients [Evidence Level A]. a. For facilities without a dedicated stroke unit, the facility must strive to focus care on the priority elements identified for comprehensive stroke care delivery (including clustering patients, interdisciplinary team, access to early rehabilitation, stroke care protocols, case rounds, patient education). Refer Box 8A for Optimal Inpatient Stroke Care criteria.
ii. The core interdisciplinary team on the stroke unit should consist of healthcare professionals with stroke expertise including physicians, nurses, occupational therapists, physiotherapists, speech-language pathologists, social workers, and clinical nutritionists (dietitians) [Evidence Level A]. a. All stroke teams should include hospital pharmacists to promote patient safety, medication reconciliation, provide education to the team and patients/family regarding medication(s) (especially side effects, adverse effects, interactions), discussions regarding adherence, and discharge planning (such as special needs for patients, e.g., individual dosing packages) [ iv. Any child admitted to hospital with stroke should be managed in a center with pediatric stroke expertise when available; if there is no access to specialized pediatric services, children with stroke should be managed using standardized pediatric stroke protocols [Evidence Level B]. a. It is recognized that not all hospitals are able to deliver all of the stroke unit elements, and every hospital should be Taking
Action to establish protocols and processes of care to implement as many elements as possible to achieve optimal stroke care delivery within their geographic location, hospital volumes, and resource availability (human, equipment, and funding). h. Dysphagia screening protocols in place to assess all stroke patients without prolonged time delays prior to commencing oral nutrition and oral medications;
i. Access to post-acute rehabilitation services, including inpatient, community-based, and/or early supported discharge therapy;
j. Discharge planning starting as soon as possible after admission, and anticipating discharge needs to facilitate smooth transitions;
k. Daily/bi-weekly patient care rounds with interdisciplinary stroke team to conduct case reviews, discuss patient management issues, family concerns or needs, and discharge planning (discharge or transition to the next step in their care, timing, transition requirements); International Journal of Stroke, 13 (9) Section 9: Inpatient prevention and management of complications following stroke Despite the best care, patients remain at high risk of medical complications, which are relatively common following stroke. They are associated with increased mortality, lengths of hospital stay, and higher cost. Therefore, appropriate investigations and management strategies should be implemented for all hospitalized patients to avoid complications and improve the odds of a good recovery. Estimates of the percentage of patients who experience at least one medical complication during hospitalization vary widely from 25% 65 to 85%. 66 Complications tend to occur more frequently in older patients, who often have multimorbidity and patients with more severe strokes. Some of the most commonly cited complications include urinary tract infections, fever, pneumonia, and deep vein thrombosis. [67] [68] [69] Controversy continues as to the benefit of early mobilization. Although the primary endpoint of the AVERT trial 70 indicated early mobilization reduced the odds of a good outcome at three months (OR ¼ 0.73, 95% CI 0.59-0.90, p ¼ 0.004), a prespecified dose-response analysis suggested that shorter, more frequent mobilizations early after acute stroke were associated with improved odds of favorable outcome, while increased amount (minutes per day) of mobilization reduced the odds. 
Cardiovascular investigations
i. For patients being investigated for an acute embolic ischemic stroke or TIA of undetermined source whose initial short-term ECG monitoring does not reveal atrial fibrillation but a cardioembolic mechanism is suspected, prolonged ECG monitoring for at least two weeks is recommended to improve detection of paroxysmal atrial fibrillation in selected patients aged !55 years who are not already receiving anticoagulant therapy but would be potential anticoagulant candidates [Evidence Level A]. Refer to CSBPR Secondary Prevention of Stroke Module for additional guidance in management of patients with stroke and atrial fibrillation.
ii. Echocardiography, either 2D or transesophageal, should be considered for patients with suspected embolic stroke and normal neurovascular imaging [Evidence Level B] as well as no contraindications for anticoagulant therapy. This is particularly relevant for younger adults with stroke or TIA and unknown etiology.
iii. Children International Journal of Stroke, 13 (9) Note: Contraindications to early mobilization include, but are not restricted to, patients who have had an arterial puncture for an interventional procedure, unstable medical conditions, low oxygen saturation, and/or lower limb fracture or injury. ii. All stroke patients should be screened for urinary incontinence and retention (with or without overflow), fecal incontinence, and constipation [Evidence Level C].
iii. The use of a portable ultrasound machine is recommended as the preferred noninvasive painless method for assessing postvoid residual [Evidence Level C].
iv. Stroke patients with urinary incontinence should be assessed by trained personnel using a structured functional assessment to determine cause and develop an individualized management plan [Evidence Level B].
Section 10: Advance care planning
Advance care planning (ACP) is a process through which a patient, in consultation with healthcare providers and family members make decisions regarding their health care, should they become incapable of participating in decision-making. Ideally, this process takes place before stroke or other life-threatening illness occurs, to help mitigate the anxiety associated with the uncertainty of stroke prognosis and recovery, and the many complex decisions that may need to be made. Elements of advance care planning include the patients' prognosis, treatment options, goals of care, and the identification and documentation of end-of-life wishes. Research suggests that less than 50% of adults have had these conversations with family members and that ACP discussions more frequently occur when patients and families are faced with a serious or life-threatening illness. 
Oral Care
i. Upon or soon after admission, all stroke patients should have an oral/dental assessment, including screening for signs of dental disease, level of oral care, and appliances [Evidence Level C].
ii. For patients wearing a full or partial denture it should be determined if they have the neuromotor skills to safely wear and use the appliance(s) [Evidence Level C].
iii. An appropriate oral care protocol should be used for every patient with stroke, including those who use dentures [Evidence Level C]. The oral care protocol should be consistent with the Canadian Dental Association recommendations [Evidence Level B] and should address areas such as frequency of oral care (ideally after meals and before bedtime); types of oral care products (toothpaste, floss, and mouthwash); and management for patients with dysphagia.
vi. If concerns with implementing an oral care protocol are identified, consider consulting a dentist, occupational therapist, speech-language pathologist, and/or a dental hygienist [Evidence Level C].
v. If concerns are identified with oral health and/or appliances, patients should be referred to a dentist for consultation and management as soon as possible [Evidence Level C]. ii. The advance care planning conversation should be revisited periodically, such as when there is a change in the patient's health status [Evidence Level B].
iii. The interdisciplinary team should have the appropriate communication skills and knowledge to address the physical, spiritual, cultural, psychological, ethical, and social needs of stroke patients, their families, and informal caregivers [Evidence Level C].
International Journal of Stroke, 13 (9) Section 11: Palliative and end-of-life care
Palliative care is a comprehensive approach to end of life care that aims to control pain, provide comfort, improve quality of life, and effectively manage patients' and their families' psychosocial needs. Decisions to withhold or withdraw life-prolonging treatments after stroke affect a substantial proportion of patients who have experienced a severe stroke; therefore, palliative care is an important component of stroke care. The most commonly identified stroke-associated palliative needs of patients identified included pain, respiratory secretions, dyspnea, agitation, and psychological distress. 72 Given the multifaceted nature of stroke care, the core elements of palliative care should be in routine practice across the various providers of a stroke team (e.g., neurologist, nurses, and therapists) and across multiple settings (ED, acute rehabilitation unit, and nursing homes).
a. Respectful discussion of patient's values and wishes should be balanced with information regarding medically appropriate treatment related to ongoing stroke management and future medical care [Evidence Level C].
iv. Capacity-related provincial legislation should be reviewed and appropriate substitute decision-makers should be identified if a survivor is deemed incapable of making specific decisions re: their personal health care and/or discharge-related finances [Evidence Level C].
Definitions:
Palliative care is an approach that focuses on comfort and quality of life for those affected by life-limiting illness, such as large hemispheric strokes, and severe hemorrhagic stroke. It aims to prevent and relieve physical, social, psychological, or spiritual suffering of stroke patients, their families and informal caregivers. Palliative care can complement life-prolonging or diseasemodifying therapies post-stroke and need not be reserved for those whose death is imminent.
A palliative approach to care refers to palliative care that is provided by non-palliative care specialists, i.e., the basic symptom management and basic psychosocial care that all clinicians provide to patients and their families.
End-of-life care is part of the palliative approach and is the management and treatment of dying patients as well as their families and informal caregivers. The end-of-life period often involves a period of change (e.g., worsening functional status) rather than an acute event.
Goals of care for palliative care: In the event of a potentially poor prognosis, the medical team may initiate a ''goals of care'' discussion with the individual and/or their substitute decision-maker. This conversation would have the objective of establishing consensus on a direction of care and would incorporate the individual's previous wishes/advanced care planning as well as their current status and needs. Some potential topics of discussion may be: preferred location of palliation, the cessation of certain medical interventions, comfort care options, and preferences in the event of immanent death (e.g., resuscitation). The intent is to then have a written communication for the healthcare team to assist in the provision of individualized palliative care in a timely manner. Health status can change over time and this written plan should be reviewed in conjunction with shifts in status or changes in the care team. The goals of care can be amended or revised at any time by the individual and/or substitute decision-maker.
Section 11: Recommendations for palliative and end-of-life care
11.0 A palliative care approach should be applied when there has been a catastrophic stroke or a stroke in the setting of significant pre-existing comorbidity, to optimize care for these patients, their families, and informal caregivers [Evidence Level B]. i. The interdisciplinary stroke team should have discussions with the patient and decision-makers regarding the patient's current state and likely progression of the effects of the stroke, and come to agreement on the general direction of care-whether care will focus on comfort or focus on life prolongation and functional improvement [Evidence Level B].
ii. Based on decisions regarding the direction of care (i), the interdisciplinary stroke team should communicate with patients, decision-makers, families, and informal caregivers on an ongoing basis, and provide information and counseling regarding who have personally experienced an acute stroke as well as their family and informal caregivers. This collaboration brings strength and consistency to stroke care coordination and delivery which leads to increased efficiencies and better outcomes. Challenges and controversies have been encountered as a result of recent advances in stroke care. With the clear benefits of EVT demonstrated, the question as to which patients are the best candidates for the procedure persists and issues of supply and demand as well as overall impact within a publicly funded healthcare system have arisen. The extended time window of up to 24 h, for highly selected patients, will increase demand for the procedure, resulting in an increased number of patients who will require advanced neuroimaging, including CTA and CTP (or MRA and MRP). However, not all primary stroke centers can perform such investigations due to older generation CT scanners, a lack of trained personnel, or funding for out-of-hours on-call staffing. Consequently, hospitals capable of advanced imaging may not be able to manage the increased volumes of patients who may be diverted or transferred to them. ED personnel are also concerned about increased demand. There have been debates related to the issue of whether all stroke patients should be transported directly to comprehensive stroke centers versus stopping at the closest primary stroke center for imaging and initiation of intravenous thrombolysis for eligible patients before determining appropriateness of transferring to an endovascular enabled hospital. [73] [74] [75] In order to answer these questions, valid data are required. As stroke systems evolve, it is imperative that data collection systems are built that facilitate close monitoring of treatment access, process times, and patient outcomes. Additional indicators to be considered include home time in the first 90 days, functional outcomes at 90 days, 76 and patient-reported outcomes such as quality of life 77 and caregiver burden. 78, 79 These recommendations are intended to drive systems change and quality improvement for acute stroke care. The recommendations continue to be a work in progress and are regularly updated every two to three years to integrate newly released data to help maximize patient outcomes from this disabling disease.
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